http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#Head
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#assertion
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#provenance
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#pubinfo
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#assertion
http://purl.obolibrary.org/obo/DOID_10763
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_10763
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00264
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#association
http://www.w3.org/2000/01/rdf-schema#label
metoprolol succinate extended release tablets metoprolol succinate is a beta selective adrenoceptor blocking agent 1 metoprolol succinate extended release tablets are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and non fatal cardiovascular events primarily strokes and myocardial infarctions 1 1 1 angina pectoris 2 1 2 heart failure for the treatment of stable symptomatic nyha class ii or iii heart failure of ischemic hypertensive or cardiomyopathic origin 3 1 3 metoprolol succinate extended release tablets are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure lowers the risk of fatal and non fatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than 1 drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy metoprolol succinate extended release tablets may be administered with other antihypertensive agents metoprolol succinate extended release tablets are indicated in the long term treatment of angina pectoris to reduce angina attacks and to improve exercise tolerance metoprolol succinate extended release tablets are indicated for the treatment of stable symptomatic nyha class ii or iii heart failure of ischemic hypertensive or cardiomyopathic origin it was studied in patients already receiving ace inhibitors diuretics and in the majority of cases digitalis in this population metoprolol succinate extended release tablets decreased the rate of mortality plus hospitalization largely through a reduction in cardiovascular mortality and hospitalizations for heart failure
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00264
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#provenance
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#pubinfo
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#sig
http://purl.org/nanopub/x/hasSignature
h9kJBWO54JCGq6K1HGmr7DmYVsW6ROooJO9YVSGlCqKoeKss3wVUcVDPcdsMf6xEoHsOrNp8dsRTrLe8Klq7rKvs40h1x8O1KNmAA1VW7F+guflfnG0wPfH3jdhVEbrxyFgRy3VYqglQdSsg08x5P1p04ySvEz7svPACfzbNETU=
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ
http://purl.org/dc/terms/created
2021-06-12T15:46:48.494+02:00
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAcR05-hyp9rC6_-wTwzLfjQOWt3Xq5lGDTiKpDayhoyQ
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs